PNCA2
MCID: PNC111
MIFTS: 26

Pancreatic Cancer 2 (PNCA2)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pancreatic Cancer 2

MalaCards integrated aliases for Pancreatic Cancer 2:

Name: Pancreatic Cancer 2 57 72 29 6
Pnca2 57 72
Cancer, Pancreatic, Susceptibility to, Type 2 39
Pancreatic Cancer, Susceptibility to, 2 57

Classifications:



External Ids:

OMIM® 57 613347
MeSH 44 D010190
MedGen 41 C3150546
SNOMED-CT via HPO 68 126859007 363418001

Summaries for Pancreatic Cancer 2

UniProtKB/Swiss-Prot : 72 Pancreatic cancer 2: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MalaCards based summary : Pancreatic Cancer 2, also known as pnca2, is related to pancreatic cancer and mental retardation, skeletal dysplasia, and abducens palsy. An important gene associated with Pancreatic Cancer 2 is BRCA2 (BRCA2 DNA Repair Associated). Affiliated tissues include pancreas and lymph node, and related phenotype is neoplasm of the pancreas.

More information from OMIM: 613347

Related Diseases for Pancreatic Cancer 2

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4
Pancreatic Cancer 5

Diseases related to Pancreatic Cancer 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 10.0
2 mental retardation, skeletal dysplasia, and abducens palsy 9.8
3 x-linked skeletal dysplasia-intellectual disability syndrome 9.8

Symptoms & Phenotypes for Pancreatic Cancer 2

Human phenotypes related to Pancreatic Cancer 2:

31
# Description HPO Frequency HPO Source Accession
1 neoplasm of the pancreas 31 HP:0002894

Clinical features from OMIM®:

613347 (Updated 05-Apr-2021)

Drugs & Therapeutics for Pancreatic Cancer 2

Search Clinical Trials , NIH Clinical Center for Pancreatic Cancer 2

Genetic Tests for Pancreatic Cancer 2

Genetic tests related to Pancreatic Cancer 2:

# Genetic test Affiliating Genes
1 Pancreatic Cancer 2 29 BRCA2

Anatomical Context for Pancreatic Cancer 2

MalaCards organs/tissues related to Pancreatic Cancer 2:

40
Pancreas, Lymph Node

Publications for Pancreatic Cancer 2

Articles related to Pancreatic Cancer 2:

(show top 50) (show all 54)
# Title Authors PMID Year
1
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. 57
31157963 2019
2
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 57
25356972 2015
3
Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. 57
15912495 2005
4
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. 57
12097290 2002
5
Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. 57
9140390 1997
6
Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. 57
7597059 1995
7
Comparative genomic analysis of tumors: detection of DNA losses and amplification. 57
7816807 1995
8
Mercury in Pancreatic Cells of People with and without Pancreatic Cancer. 61
33276658 2020
9
Feasibility and Safety of Laparoscopic Radical Distal Pancreatosplenectomy with Adrenalectomy in Advanced Pancreatic Cancer. 61
32474822 2020
10
Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis. 61
32125712 2020
11
Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. 61
32353313 2020
12
National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection. 61
31691112 2020
13
2-Methoxy-4-vinylphenol Attenuates Migration of Human Pancreatic Cancer Cells via Blockade of FAK and AKT Signaling. 61
31810933 2019
14
Prospective study of cancer in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry. 61
31592402 2019
15
Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. 61
30999653 2019
16
Endovascular Denervation: A New Approach for Cancer Pain Relief? 61
30414719 2018
17
Simple Clinical Score to Predict 24-Week Survival Times in Patients with Inoperable Malignant Distal Biliary Obstruction as a Tool for Selecting Palliative Metallic or Plastic Stents. 61
28093683 2018
18
[A Case of Resection for Lymph Node Recurrence around the Inferior Vena Cava after Radical Surgery of Undifferentiated Carcinoma of the Pancreatic Head Region]. 61
29483447 2018
19
[A Case of Gemcitabine and Nab-Paclitaxel Therapy for Multiple Metastatic Pancreatic Cancer]. 61
29394789 2017
20
Clinical Management: Metastatic Disease. 61
29189332 2017
21
Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. 61
27323855 2016
22
Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. 61
26995276 2016
23
Metachronous colonic metastasis from pancreatic cancer presenting as mechanical obstruction: a case report. 61
25735449 2015
24
Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. 61
25065594 2015
25
[Palliative surgery for malignant bowel obstruction in patients with advanced and recurrent gastroenterological cancer]. 61
24393893 2013
26
B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. 61
22797826 2012
27
Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England. 61
22365494 2012
28
European cancer mortality predictions for the year 2012. 61
22373539 2012
29
Laparoscopic major gynecologic surgery in patients with prior laparotomy bowel resection. 61
22643497 2011
30
Strength of the evidence: adjuvant therapy for resected pancreatic cancer. 61
18157582 2008
31
[Assessment of efficacy of arterial infusion chemotherapy with gemcitabine for four cases of advanced pancreatic cancer]. 61
18219883 2007
32
Endosonography- vs. endoscopic retrograde cholangiopancreatography-based strategies in the evaluation of suspected common bile duct stones in patients with normal transabdominal imaging. 61
17894658 2007
33
Hepato-pancreato-biliary fat: the good, the bad and the ugly. 61
18333122 2007
34
[Combined multiple organ resection in 16 patients with adenocarcinoma of the body or tail of the pancreas]. 61
16274034 2005
35
Diagnosis and treatment of pancreatolithiasis: report of 16 cases. 61
15730938 2005
36
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis. 61
15647194 2005
37
[Distal pancreatectomy: one technique with several indications]. 61
16420878 2005
38
Intraductal pancreatic carcinoma associated with pancreas divisum. 61
12828523 2003
39
Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. 61
11961486 2002
40
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. 61
11207041 2001
41
[Randomized prospective study to compare the efficiency between standard plastic and polyurethane stents in biliary tract malignant obstruction]. 61
11144946 2000
42
Serum growth factors in patients with pancreatic cancer. 61
10050105 1999
43
The splice-pattern of CD44 is altered in chronic pancreatitis exhibiting dysplastic changes. 61
9737888 1998
44
Thoracoscopic Splanchnicectomy for Chronic, Severe Pancreatic Pain. 61
10401100 1996
45
[Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)]. 61
8031168 1994
46
Bilateral endoscopic splanchnicectomy through a posterior thoracoscopic approach. 61
7515430 1994
47
Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. 61
8249918 1993
48
Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer. 61
8233283 1993
49
[Two different types of monoclonal antibodies against gallbladder carcinoma cell line]. 61
1770935 1991
50
Comparative histopathological findings in the pancreas of cigarette smokers and non-smokers. 61
2265410 1990

Variations for Pancreatic Cancer 2

ClinVar genetic disease variations for Pancreatic Cancer 2:

6 (show top 50) (show all 57)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRCA2 NM_000059.4(BRCA2):c.145G>T (p.Glu49Ter) SNV Pathogenic 51129 rs80358435 GRCh37: 13:32893291-32893291
GRCh38: 13:32319154-32319154
2 BRCA2 NM_000059.4(BRCA2):c.92G>A (p.Trp31Ter) SNV Pathogenic 52808 rs397508045 GRCh37: 13:32893238-32893238
GRCh38: 13:32319101-32319101
3 BRCA2 NM_000059.4(BRCA2):c.100G>T (p.Glu34Ter) SNV Pathogenic 51041 rs80358391 GRCh37: 13:32893246-32893246
GRCh38: 13:32319109-32319109
4 BRCA2 NM_000059.4(BRCA2):c.3109C>T (p.Gln1037Ter) SNV Pathogenic 37819 rs80358557 GRCh37: 13:32911601-32911601
GRCh38: 13:32337464-32337464
5 BRCA2 NM_000059.4(BRCA2):c.4965C>G (p.Tyr1655Ter) SNV Pathogenic 37936 rs80358721 GRCh37: 13:32913457-32913457
GRCh38: 13:32339320-32339320
6 BRCA2 NM_000059.4(BRCA2):c.6952C>T (p.Arg2318Ter) SNV Pathogenic 38076 rs80358920 GRCh37: 13:32920978-32920978
GRCh38: 13:32346841-32346841
7 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 GRCh37: 13:32954050-32954050
GRCh38: 13:32379913-32379913
8 BRCA2 NM_000059.3(BRCA2):c.5791C>T (p.Gln1931Ter) SNV Pathogenic 51939 rs80358807 GRCh37: 13:32914283-32914283
GRCh38: 13:32340146-32340146
9 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 GRCh37: 13:32954050-32954050
GRCh38: 13:32379913-32379913
10 BRCA2 NM_000059.4(BRCA2):c.5857G>T (p.Glu1953Ter) SNV Pathogenic 51952 rs80358814 GRCh37: 13:32914349-32914349
GRCh38: 13:32340212-32340212
11 BRCA2 NM_000059.3(BRCA2):c.1399A>T (p.Lys467Ter) SNV Pathogenic 51118 rs80358427 GRCh37: 13:32907014-32907014
GRCh38: 13:32332877-32332877
12 BRCA2 NM_000059.3(BRCA2):c.4243G>T (p.Glu1415Ter) SNV Pathogenic 37890 rs397507327 GRCh37: 13:32912735-32912735
GRCh38: 13:32338598-32338598
13 BRCA2 NM_000059.4(BRCA2):c.6656C>G (p.Ser2219Ter) SNV Pathogenic 52149 rs80358893 GRCh37: 13:32915148-32915148
GRCh38: 13:32341011-32341011
14 BRCA2 NM_000059.4(BRCA2):c.7879A>T (p.Ile2627Phe) SNV Pathogenic 52430 rs80359014 GRCh37: 13:32936733-32936733
GRCh38: 13:32362596-32362596
15 BRCA2 NM_000059.4(BRCA2):c.7988A>T (p.Glu2663Val) SNV Pathogenic 52462 rs80359031 GRCh37: 13:32937327-32937327
GRCh38: 13:32363190-32363190
16 BRCA2 NM_000059.4(BRCA2):c.8167G>C (p.Asp2723His) SNV Pathogenic 52515 rs41293511 GRCh37: 13:32937506-32937506
GRCh38: 13:32363369-32363369
17 BRCA2 NM_000059.4(BRCA2):c.8488-1G>A SNV Pathogenic 38164 rs397507404 GRCh37: 13:32945092-32945092
GRCh38: 13:32370955-32370955
18 BRCA2 NM_000059.4(BRCA2):c.9294C>G (p.Tyr3098Ter) SNV Pathogenic 38229 rs80359200 GRCh37: 13:32968863-32968863
GRCh38: 13:32394726-32394726
19 BRCA2 NM_000059.4(BRCA2):c.9382C>T (p.Arg3128Ter) SNV Pathogenic 52826 rs80359212 GRCh37: 13:32968951-32968951
GRCh38: 13:32394814-32394814
20 BRCA2 NM_000059.4(BRCA2):c.5682C>G (p.Tyr1894Ter) SNV Pathogenic 37989 rs41293497 GRCh37: 13:32914174-32914174
GRCh38: 13:32340037-32340037
21 BRCA2 NM_000059.4(BRCA2):c.7480C>T (p.Arg2494Ter) SNV Pathogenic 38099 rs80358972 GRCh37: 13:32930609-32930609
GRCh38: 13:32356472-32356472
22 BRCA2 NM_000059.4(BRCA2):c.5946del (p.Ser1982fs) Deletion risk factor 9325 rs80359550 GRCh37: 13:32914438-32914438
GRCh38: 13:32340301-32340301
23 BRCA2 NM_000059.4(BRCA2):c.3835A>G (p.Asn1279Asp) SNV Uncertain significance 51534 rs80358626 GRCh37: 13:32912327-32912327
GRCh38: 13:32338190-32338190
24 BRCA2 NM_000059.3(BRCA2):c.7628A>G (p.Tyr2543Cys) SNV Uncertain significance 96855 rs431825354 GRCh37: 13:32931889-32931889
GRCh38: 13:32357752-32357752
25 BRCA2 NM_000059.3(BRCA2):c.7781A>G (p.Lys2594Arg) SNV Uncertain significance 234138 rs876660874 GRCh37: 13:32932042-32932042
GRCh38: 13:32357905-32357905
26 BRCA2 NM_000059.3(BRCA2):c.8007A>T (p.Arg2669Ser) SNV Uncertain significance 183981 rs143999963 GRCh37: 13:32937346-32937346
GRCh38: 13:32363209-32363209
27 BRCA2 NM_000059.3(BRCA2):c.9218A>G (p.Asp3073Gly) SNV Uncertain significance 52779 rs80359186 GRCh37: 13:32954244-32954244
GRCh38: 13:32380107-32380107
28 BRCA2 NM_000059.3(BRCA2):c.9538C>T (p.Leu3180Phe) SNV Uncertain significance 52865 rs200598289 GRCh37: 13:32971071-32971071
GRCh38: 13:32396934-32396934
29 BRCA2 NM_000059.3(BRCA2):c.6013G>T (p.Asp2005Tyr) SNV Uncertain significance 141457 rs587781760 GRCh37: 13:32914505-32914505
GRCh38: 13:32340368-32340368
30 BRCA2 NM_000059.3(BRCA2):c.2186T>C (p.Ile729Thr) SNV Uncertain significance 96780 rs431825296 GRCh37: 13:32910678-32910678
GRCh38: 13:32336541-32336541
31 BRCA2 NM_000059.3(BRCA2):c.7693G>A (p.Glu2565Lys) SNV Uncertain significance 441448 rs764761862 GRCh37: 13:32931954-32931954
GRCh38: 13:32357817-32357817
32 BRCA2 NM_000059.3(BRCA2):c.7954G>A (p.Val2652Met) SNV Uncertain significance 462460 rs1466452770 GRCh37: 13:32936808-32936808
GRCh38: 13:32362671-32362671
33 BRCA2 NM_000059.4(BRCA2):c.7992T>G (p.Ile2664Met) SNV Uncertain significance 182247 rs80359800 GRCh37: 13:32937331-32937331
GRCh38: 13:32363194-32363194
34 BRCA2 NM_000059.3(BRCA2):c.9530A>G (p.Glu3177Gly) SNV Uncertain significance 230066 rs876658365 GRCh37: 13:32971063-32971063
GRCh38: 13:32396926-32396926
35 BRCA2 NM_000059.3(BRCA2):c.7625C>T (p.Thr2542Met) SNV Uncertain significance 96854 rs80358989 GRCh37: 13:32931886-32931886
GRCh38: 13:32357749-32357749
36 BRCA2 NM_000059.3(BRCA2):c.7051G>A (p.Ala2351Thr) SNV Uncertain significance 52256 rs80358930 GRCh37: 13:32929041-32929041
GRCh38: 13:32354904-32354904
37 BRCA2 NM_000059.3(BRCA2):c.3808G>A (p.Val1270Ile) SNV Uncertain significance 231069 rs876658938 GRCh37: 13:32912300-32912300
GRCh38: 13:32338163-32338163
38 BRCA2 NM_000059.3(BRCA2):c.6148G>A (p.Val2050Ile) SNV Uncertain significance 52019 rs80358854 GRCh37: 13:32914640-32914640
GRCh38: 13:32340503-32340503
39 BRCA2 NM_000059.3(BRCA2):c.6818G>A (p.Arg2273Lys) SNV Uncertain significance 142005 rs587782174 GRCh37: 13:32915310-32915310
GRCh38: 13:32341173-32341173
40 BRCA2 NM_000059.3(BRCA2):c.8817G>C (p.Lys2939Asn) SNV Uncertain significance 38187 rs397507414 GRCh37: 13:32953516-32953516
GRCh38: 13:32379379-32379379
41 BRCA2 NM_000059.3(BRCA2):c.1433C>A (p.Thr478Lys) SNV Uncertain significance 96764 rs431825282 GRCh37: 13:32907048-32907048
GRCh38: 13:32332911-32332911
42 BRCA2 NM_000059.3(BRCA2):c.2122T>A (p.Ser708Thr) SNV Uncertain significance 51246 rs80358488 GRCh37: 13:32910614-32910614
GRCh38: 13:32336477-32336477
43 BRCA2 NM_000059.4(BRCA2):c.2405A>G (p.Asn802Ser) SNV Uncertain significance 234566 rs876661089 GRCh37: 13:32910897-32910897
GRCh38: 13:32336760-32336760
44 BRCA2 NM_000059.3(BRCA2):c.2908G>A (p.Asp970Asn) SNV Uncertain significance 37806 rs397507295 GRCh37: 13:32911400-32911400
GRCh38: 13:32337263-32337263
45 BRCA2 NM_000059.3(BRCA2):c.4478A>G (p.Glu1493Gly) SNV Uncertain significance 126045 rs80358679 GRCh37: 13:32912970-32912970
GRCh38: 13:32338833-32338833
46 BRCA2 NM_000059.3(BRCA2):c.4535G>A (p.Arg1512His) SNV Uncertain significance 51661 rs80358685 GRCh37: 13:32913027-32913027
GRCh38: 13:32338890-32338890
47 BRCA2 NM_000059.3(BRCA2):c.4825A>G (p.Thr1609Ala) SNV Uncertain significance 231512 rs876659201 GRCh37: 13:32913317-32913317
GRCh38: 13:32339180-32339180
48 BRCA2 NM_000059.3(BRCA2):c.5747A>G (p.His1916Arg) SNV Uncertain significance 96828 rs431825334 GRCh37: 13:32914239-32914239
GRCh38: 13:32340102-32340102
49 BRCA2 NM_000059.3(BRCA2):c.5962G>A (p.Val1988Ile) SNV Uncertain significance 91430 rs28897739 GRCh37: 13:32914454-32914454
GRCh38: 13:32340317-32340317
50 BRCA2 NM_000059.3(BRCA2):c.5986G>T (p.Ala1996Ser) SNV Uncertain significance 38012 rs80358833 GRCh37: 13:32914478-32914478
GRCh38: 13:32340341-32340341

Expression for Pancreatic Cancer 2

Search GEO for disease gene expression data for Pancreatic Cancer 2.

Pathways for Pancreatic Cancer 2

GO Terms for Pancreatic Cancer 2

Sources for Pancreatic Cancer 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....